ACHN Achillion Pharmaceuticals Inc.

Achillion to Present at the 2018 JMP Securities Life Sciences Conference

Achillion to Present at the 2018 JMP Securities Life Sciences Conference

NEW HAVEN, Conn., June 14, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present at the 2018 JMP Securities Life Sciences Conference on Thursday, June 21, 2018, at 9:00 a.m. ET at the St. Regis New York Hotel, in New York, NY.

The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its capabilities across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to build a platform of potent and specific complement factor D inhibitors for AP-mediated diseases. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at 

Investors & Media:

Glenn Schulman, PharmD, MPH

Achillion Pharmaceuticals, Inc.

Tel. (203) 752-5510

EN
14/06/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Achillion Pharmaceuticals Inc.

 PRESS RELEASE

Achillion Shareholders Approve Agreement to be Acquired by Alexion

Achillion Shareholders Approve Agreement to be Acquired by Alexion BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN). Achillion continues to expect the transaction to close in the first half of 2020, subject to expiration or termination of the applicable waiting period un...

 PRESS RELEASE

Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4...

Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting – 2.4 g/dL mean increase in hemoglobin at 24 weeks –– Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis –- Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020 - BLUE BELL, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) --  Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company de...

Increased risk weighs on ACHILLION PHARMS.INCO., penalising its ratin...

The independent financial analyst theScreener just lowered the general evaluation of ACHILLION PHARMS.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date December 6, 2019, the c...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch